Cargando…

The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer

Patients with positive Her-2/neu breast cancer and a high risk of recurrence are known to benefit from the addition of the dual blockade of Her-2/neu with Trastuzumab and Pertuzumab to the neoadjuvant chemotherapy, a combination which has been demonstrated to give a higher rate of a complete patholo...

Descripción completa

Detalles Bibliográficos
Autores principales: Pop, Lucian, Suciu, Ioan Dumitru, Ionescu, Olivia, Ionescu, Paris, Toader, Oana Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Carol Davila University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993292/
https://www.ncbi.nlm.nih.gov/pubmed/32025249
http://dx.doi.org/10.25122/jml-2019-0115

Ejemplares similares